Components of the tumor immune microenvironment based on m-IHC correlate with prognosis and subtype of triple-negative breast cancer

被引：4

作者：

Lin, Luyi ^{[1
,4
]}

Li, Haiming ^{[1
,4
]}

Wang, Xin ^{[2
,4
]}

Wang, Zezhou ^{[3
,4
,5
]}

Su, Guanhua ^{[4
,6
]}

Zhou, Jiayin ^{[1
,4
]}

Sun, Shiyun ^{[1
,4
]}

Ma, Xiaowen ^{[1
,4
]}

Chen, Yan ^{[7
]}

You, Chao ^{[1
,4
,8
]}

Gu, Yajia ^{[1
,4
,8
]}

机构：

[1] Fudan Univ, Shanghai Canc Ctr, Dept Radiol, Shanghai, Peoples R China

[2] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai, Peoples R China

[3] Fudan Univ, Shanghai Canc Ctr, Dept Canc Prevent, Shanghai, Peoples R China

[4] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China

[5] Shanghai Municipal Hosp Oncol Specialist Alliance, Shanghai, Peoples R China

[6] Fudan Univ, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai Canc Ctr, Shanghai, Peoples R China

[7] Univ Nottingham, Sch Med, Div Canc & Stem Cells, Nottingham, England

[8] Fudan Univ Canc Ctr, Dept Radiol, 270 Dongan Rd, Shanghai 200032, Peoples R China

来源：

CANCER MEDICINE | 2023年 / 12卷 / 24期

关键词：

multiplex IHC; prognosis; subtype; triple-negative breast cancer; tumor immune microenvironment;

D O I：

10.1002/cam4.6718

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background and Aim: The spatial distribution and interactions of cells in the tumor immune microenvironment (TIME) might be related to the different responses of triple-negative breast cancer (TNBC) to immunomodulators. The potential of multiplex IHC (m-IHC) in evaluating the TIME has been reported, but the efficacy is insufficient. We aimed to research whether m-IHC results could be used to reflect the TIME, and thus to predict prognosis and complement the TNBC subtyping system.Methods: The clinical, imaging, and prognosis data for 86 TNBC patients were retrospectively reviewed. CD3, CD4, CD8, Foxp3, PD-L1, and Pan-CK markers were stained by m-IHC. Particular cell spatial distributions and interactions in the TIME were evaluated with the HALO multispectral analysis platform. Then, we calculated the prognostic value of components of the TIME and their correlations with TNBC transcriptomic subtypes and MRI radiomic features reflecting TNBC subtypes.Results: The components of the TIME score were established by m-IHC and demonstrated positive prognostic value for TNBC (p = 0.0047, 0.039, <0.0001 for DMFS, RFS, and OS). The score was calculated from several indicators, including Treg% in the tumor core (TC) or stromal area (SA), PD-L1(+) cell% in the SA, CD3 + cell% in the TC, and PD-L1(+)/CD8(+ )cells in the invasive margin and SA. According to the TNBC subtyping system, a few TIME indicators were significantly different in different subtypes and significantly correlated with MRI radiomic features reflecting TNBC subtypes.Conclusion: We demonstrated that the m-IHC-based quantitative score and indicators related to the spatial distribution and interactions of cells in the TIME can aid in the accurate diagnosis of TNBC in terms of prognosis and classification.

引用

页码：21639 / 21650

页数：12

共 28 条

[1] 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) [J].

Cardoso, F. ;

Senkus, E. ;

Costa, A. ;

Papadopoulos, E. ;

Aapro, M. ;

Andre, F. ;

Harbeck, N. ;

Aguilar Lopez, B. ;

Barrios, C. H. ;

Bergh, J. ;

Biganzoli, L. ;

Boers-Doers, C. B. ;

Cardoso, M. J. ;

Carey, L. A. ;

Cortes, J. ;

Curigliano, G. ;

Dieras, V. ;

El Saghir, N. S. ;

Eniu, A. ;

Fallowfield, L. ;

Francis, P. A. ;

Gelmon, K. ;

Johnston, S. R. D. ;

Kaufmann, B. ;

Koppikar, S. ;

Krop, I. E. ;

Mayer, M. ;

Nakigudde, G. ;

Offersen, B. V. ;

Ohno, S. ;

Pagani, O. ;

Paluch-Shimon, S. ;

Penault-Llorca, F. ;

Prat, A. ;

Rugo, H. S. ;

Sledge, G. W. ;

Spence, D. ;

Thomssen, C. ;

Vorobiof, D. A. ;

Xu, B. ;

Norton, L. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2018, 29 (08) :1634-1657

[2] Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial [J].

Chen, Li ;

Jiang, Yi-Zhou ;

Wu, Song-Yang ;

Wu, Jiong ;

Di, Gen -Hong ;

Liu, Guang-Yu ;

Yu, Ke-Da ;

Fan, Lei ;

Li, Jun-Jie ;

Hou, Yi-Feng ;

Hu, Zhen ;

Chen, Can-Ming ;

Huang, Xiao-Yan ;

Cao, A-Yong ;

Hu, Xin ;

Zhao, Shen ;

Ma, Xiao-Yan ;

Xu, Ying ;

Sun, Xiang-Jie ;

Chai, Wen -Jun ;

Guo, Xiaomao ;

Chen, Xizi ;

Xu, Yanhui ;

Zhu, Xiao-Yu ;

Zou, Jian-Jun ;

Yang, Wen-Tao ;

Wang, Zhong-Hua ;

Shao, Zhi-Ming .

CLINICAL CANCER RESEARCH, 2022, 28 (13) :2807-2817

[3] Triple-negative breast cancer: Clinical features and patterns of recurrence [J].

Dent, Rebecca ;

Trudeau, Maureen ;

Pritchard, Kathleen I. ;

Hanna, Wedad M. ;

Kahn, Harriet K. ;

Sawka, Carol A. ;

Lickley, Lavina A. ;

Rawlinson, Ellen ;

Sun, Ping ;

Narod, Steven A. .

CLINICAL CANCER RESEARCH, 2007, 13 (15) :4429-4434

[4] Radiogenomic signatures reveal multiscale intratumour heterogeneity associated with biological functions and survival in breast cancer [J].

Fan, Ming ;

Xia, Pingping ;

Clarke, Robert ;

Wang, Yue ;

Li, Lihua .

NATURE COMMUNICATIONS, 2020, 11 (01)

[5] Multiparametric immune profiling in HPV-oral squamous cell cancer [J].

Feng, Zipei ;

Bethmann, Daniel ;

Kappler, Matthias ;

Ballesteros-Merino, Carmen ;

Eckert, Alexander ;

Bell, R. Bryan ;

Cheng, Allen ;

Bui, Tuan ;

Leidner, Rom ;

Urba, Walter J. ;

Johnson, Kent ;

Hoyt, Clifford ;

Bifulco, Carlo B. ;

Bukur, Juergen ;

Wickenhauser, Claudia ;

Seliger, Barbara ;

Fox, Bernard A. .

JCI INSIGHT, 2017, 2 (14)

[6] Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response [J].

Fu, Tong ;

Dai, Lei-Jie ;

Wu, Song-Yang ;

Xiao, Yi ;

Ma, Ding ;

Jiang, Yi-Zhou ;

Shao, Zhi-Ming .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)

[7] Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients [J].

Gide, Tuba N. ;

Silva, Ines P. ;

Quek, Camelia ;

Ahmed, Tasnia ;

Menzies, Alexander M. ;

Carlino, Matteo S. ;

Saw, Robyn P. M. ;

Thompson, John F. ;

Batten, Marcel ;

Long, Georgina V. ;

Scolyer, Richard A. ;

Wilmott, James S. .

ONCOIMMUNOLOGY, 2020, 9 (01)

[8] Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab [J].

Giraldo, Nicolas A. ;

Nguyen, Peter ;

Engle, Elizabeth L. ;

Kaunitz, Genevieve J. ;

Cottrell, Tricia R. ;

Berry, Sneha ;

Green, Benjamin ;

Soni, Abha ;

Cuda, Jonathan D. ;

Stein, Julie E. ;

Sunshine, Joel C. ;

Succaria, Farah ;

Xu, Haiying ;

Ogurtsova, Aleksandra ;

Danilova, Ludmila ;

Church, Candice D. ;

Miller, Natalie J. ;

Fling, Steve ;

Lundgren, Lisa ;

Ramchurren, Nirasha ;

Yearley, Jennifer H. ;

Lipson, Evan J. ;

Cheever, Mac ;

Anders, Robert A. ;

Nghiem, Paul T. ;

Topalian, Suzanne L. ;

Taube, Janis M. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[9] Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer [J].

Guo, Liang ;

Cao, Chunmei ;

Goswami, Shyamal ;

Huang, Xiaoyan ;

Ma, Linxiaoxi ;

Guo, Yicheng ;

Yang, Benlong ;

Li, Teng ;

Chi, Yayun ;

Zhang, Xiaoming ;

Wu, Jiong .

CLINICAL SCIENCE, 2020, 134 (07) :711-726

[10] Quantitative high-throughput analysis of tumor infiltrating lymphocytes in breast cancer [J].

Hayashi, Kumiko ;

Nogawa, Daichi ;

Kobayashi, Maki ;

Asakawa, Ayaka ;

Ohata, Yae ;

Kitagawa, Shota ;

Kubota, Kazuishi ;

Takahashi, Hisashi ;

Yamada, Miyuki ;

Oda, Goshi ;

Nakagawa, Tsuyoshi ;

Uetake, Hiroyuki ;

Onishi, Iichiroh ;

Kinowaki, Yuko ;

Kurata, Morito ;

Kitagawa, Masanobu ;

Yamamoto, Kouhei .

FRONTIERS IN ONCOLOGY, 2022, 12

← 1 2 3 →